Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IELSG32: Primary Chemotherapy and Consolidation in Primary CNS Lymphoma
NCT01011920Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Nov 2009
- Primary completion
- Mar 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of rituximab and thiotepa in primary central nervous system lymphoma (PCNSL) (5 arms), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Complete Remission Rate After Primary Chemotherapy at 3 months and 2 Years Failure Free Survival After Second Randomization. Started Nov 2009; status: completed.
02
Drugs
rituximabthiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT01011920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011920.